Prospects for the Use of Antibodies Against Parkinson’s Disease: A Multi-Edged Sword?
Monoclonal antibodies (mAbs) show great potential for targeting α-synuclein aggregates in Parkinson’s disease. However, overcoming barriers like blood-brain barrier penetration, the need for precise target elimination, and reliable early diagnosis remain critical challenges. New approaches, such as engineered nanobodies and advanced drug delivery systems, are being developed to address these obstacles, offering promising pathways for more effective treatments and diagnostics.
Få tillgång
Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.
- Få tillgång
- Om du redan har en profil: Logga in
